Загрузка...

Bi-Monthly Blood Cancer Financial Q&A: Expert Answers to Your Treatment Costs and Support Questions

Join us for our bi-monthly financial Q&A featuring, our amazing in-house financial expert, Diahanna Vallentine!

HealthTree Foundation offers trusted education, community support, and a powerful data portal for Blood Cancer patients.

Join our newsletter to stay informed of future webinars https://htree.org/bloodcancernews

Follow HealthTree
https://x.com/HealthTree
https://www.facebook.com/healthtreeorg
https://www.instagram.com/healthtreeorg

Видео Bi-Monthly Blood Cancer Financial Q&A: Expert Answers to Your Treatment Costs and Support Questions канала HealthTree Foundation for Leukemia
HealthTree Foundation cancer cure AML CLL DLBCL FL MF MDS acute myeloid leukemia diffuse large b cell lymphoma chronic lymphocytic leukemia follicular lymphoma myelofibrosis myelodysplastic syndromes university free course online medicine expert drug doctor patient
Комментарии отсутствуют
Зарегистрируйтесь или войдите с
Информация о видео
4 февраля 2026 г. 21:25:11
00:50:07
HealthTree Foundation for Leukemia
Теги
Правообладателям
Жалоба на материал Недопустимый материал Нарушение авторских прав
Комментарии
Поделиться
Другие видео канала

What does it mean to be MRD positive? What does this mean for my long term outcomes? #AMLWhat does it mean to be MRD positive? What does this mean for my long term outcomes? #AML

Ibrutinib + Venetoclax (I+V) for #CLL: Findings from CAPTIVATE & GLOW | Paolo Ghia, MD PhD | ASH2025Ibrutinib + Venetoclax (I+V) for #CLL: Findings from CAPTIVATE & GLOW | Paolo Ghia, MD PhD | ASH2025

Nutrition During Blood Cancer Treatment: Eating Well Through Treatment and RecoveryNutrition During Blood Cancer Treatment: Eating Well Through Treatment and Recovery

What follow up appointments should be necessary before and after treatment? #CLLWhat follow up appointments should be necessary before and after treatment? #CLL

Understanding the Risk of Secondary Cancers for Chronic Lymphocytic Leukemia PatientsUnderstanding the Risk of Secondary Cancers for Chronic Lymphocytic Leukemia Patients

Chemotherapy in Treating #AcuteLymphoblasticLeukemia & Common Chemotherapy DrugChemotherapy in Treating #AcuteLymphoblasticLeukemia & Common Chemotherapy Drug

Cardiotoxicity and BTK Inhibitors: What CLL Patients Should KnowCardiotoxicity and BTK Inhibitors: What CLL Patients Should Know

What types of treatment options are available for CLL patients? #CLLWhat types of treatment options are available for CLL patients? #CLL

What is momelotinib (Ojjaara)? #myelofibrosisWhat is momelotinib (Ojjaara)? #myelofibrosis

What is the impact of diabetes on chronic lymphocytic leukemia? | #CLLWhat is the impact of diabetes on chronic lymphocytic leukemia? | #CLL

If you are MRD positive, should you continue to have MRD testing completed? #AMLIf you are MRD positive, should you continue to have MRD testing completed? #AML

When are bispecific antibodies and CAR-T cell therapy used for DLBCL? #DLBCLWhen are bispecific antibodies and CAR-T cell therapy used for DLBCL? #DLBCL

Exploring Promising Treatments and Clinical Trials for #AML Patients #MDSExploring Promising Treatments and Clinical Trials for #AML Patients #MDS

Hope on the Horizon: Top MDS & CMML Breakthroughs from ASH 2025Hope on the Horizon: Top MDS & CMML Breakthroughs from ASH 2025

Could This New BTK Degrader Change Relapsed #CLL Treatment? | Amit Agarwal, MD, PhD | #ASH25Could This New BTK Degrader Change Relapsed #CLL Treatment? | Amit Agarwal, MD, PhD | #ASH25

Imetatlistat in lower-risk MDS: Study results | Amer Zeidan, MBBS | #ASH2025Imetatlistat in lower-risk MDS: Study results | Amer Zeidan, MBBS | #ASH2025

Decoding ALL: Making Sense of Genetics and MutationsDecoding ALL: Making Sense of Genetics and Mutations

What are the common side effects of JAK2 inhibitors? #myelofibrosisWhat are the common side effects of JAK2 inhibitors? #myelofibrosis

Can Nadir Bone Marrow Predict #AML Outcomes? New Trial Data | Douglas Tremblay, MD | #ASH25Can Nadir Bone Marrow Predict #AML Outcomes? New Trial Data | Douglas Tremblay, MD | #ASH25

What are the potential benefits of taking JAK2 inhibitors for myelofibrosis? #myelofibrosisWhat are the potential benefits of taking JAK2 inhibitors for myelofibrosis? #myelofibrosis

Яндекс.Метрика
© 2008-2026 «Информационно-развлекательный портал города Верхняя Салда»
salda.ws@mail.ru salda_ws Контакты Карта портала Сообщить об ошибке Соглашения Пользовательское соглашение Соглашение о конфиденциальности Согласие на обработку персональных данных Информация для правообладателей Об использовании Cookies
Все заметки Новая заметка Страницу в заметки
Страницу в закладки Мои закладки
На информационно-развлекательном портале SALDA.WS применяются cookie-файлы. Нажимая кнопку Принять, вы подтверждаете свое согласие на их использование.
О CookiesНапомнить позжеПринять